(AVTR) Avantor - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 5.203m USD | Total Return: -42.8% in 12m

Chemicals, Lab Supplies, Filtration, Chromatography, Single-use Assemblies
Total Rating 29
Safety 74
Buy Signal -0.29
Medical Instruments & Supplies
Industry Rotation: +4.1
Market Cap: 5.20B
Avg Turnover: 70.2M
Risk 3d forecast
Volatility43.3%
VaR 5th Pctl6.88%
VaR vs Median-4.24%
Reward TTM
Sharpe Ratio-0.94
Rel. Str. IBD4.9
Rel. Str. Peer Group12.1
Character TTM
Beta0.816
Beta Downside1.257
Hurst Exponent0.490
Drawdowns 3y
Max DD73.25%
CAGR/Max DD-0.39
CAGR/Mean DD-0.97
EPS (Earnings per Share) EPS (Earnings per Share) of AVTR over the last years for every Quarter: "2021-03": 0.35, "2021-06": 0.35, "2021-09": 0.35, "2021-12": 0.36, "2022-03": 0.38, "2022-06": 0.37, "2022-09": 0.34, "2022-12": 0.32, "2023-03": 0.29, "2023-06": 0.28, "2023-09": 0.25, "2023-12": 0.25, "2024-03": 0.22, "2024-06": 0.25, "2024-09": 0.26, "2024-12": 0.27, "2025-03": 0.23, "2025-06": 0.24, "2025-09": 0.22, "2025-12": 0.22, "2026-03": 0.17,
EPS CAGR: -18.73%
EPS Trend: -87.7%
Last SUE: -3.23
Qual. Beats: -1
Revenue Revenue of AVTR over the last years for every Quarter: 2021-03: 1785.6, 2021-06: 1858.6, 2021-09: 1834.3, 2021-12: 1907.6, 2022-03: 1950.4, 2022-06: 1910.5, 2022-09: 1856.5, 2022-12: 1795, 2023-03: 1780.3, 2023-06: 1743.9, 2023-09: 1720.2, 2023-12: 1722.8, 2024-03: 1679.8, 2024-06: 1702.8, 2024-09: 1714.4, 2024-12: 1686.6, 2025-03: 1581.4, 2025-06: 1683.4, 2025-09: 1623.8, 2025-12: 1663.6, 2026-03: 1581.4,
Rev. CAGR: -4.92%
Rev. Trend: -90.3%
Last SUE: 2.06
Qual. Beats: 2

Warnings

High Debt/EBITDA (27.0) with thin interest coverage (-1.6)

Interest Coverage Ratio -1.6 is critical

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: AVTR Avantor

Avantor, Inc. (AVTR) is a global provider of mission-critical products and services for the life sciences and advanced technology industries. The company’s portfolio spans materials and consumables, specialized equipment, and comprehensive laboratory services, supporting the entire lifecycle from research and development to commercial production.

Operating within the Life Sciences Tools & Services sub-industry, Avantor utilizes a recurring revenue model driven by high-volume consumables and integrated onsite services. This sector is characterized by high switching costs due to the rigorous regulatory requirements and technical specifications inherent in biopharmaceutical manufacturing.

The company maintains a broad geographic footprint across the Americas, Europe, and Asia, serving diverse end-markets including healthcare, education, and government agencies. Detailed financial metrics and valuation trends are available on ValueRay for those conducting deeper due diligence. Since its founding in 1904, the firm has expanded from basic chemical production into complex bioprocessing solutions and clinical trial support.

Headlines to Watch Out For
  • Biopharma R&D spending levels dictate demand for high-purity chemicals and consumables
  • Recovery in single-use technology adoption drives bioprocessing revenue and margin expansion
  • Global laboratory equipment sales fluctuate based on academic and government funding cycles
  • High leverage and interest expense impact net income and capital allocation flexibility
  • Strategic cost-cutting initiatives and operational efficiencies influence long-term EBITDA margin growth
Piotroski VR‑10 (Strict) 4.0
Net Income: -551.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.64 > 1.0
NWC/Revenue: 15.83% < 20% (prev 3.71%; Δ 12.12% < -1%)
CFO/TA 0.05 > 3% & CFO 573.2m > Net Income -551.4m
Net Debt (3.54b) to EBITDA (131.1m): 26.98 < 3
Current Ratio: 1.76 > 1.5 & < 3
Outstanding Shares: last quarter (679.3m) vs 12m ago -0.45% < -2%
Gross Margin: 32.13% > 18% (prev 0.34%; Δ 3.18k% > 0.5%)
Asset Turnover: 54.63% > 50% (prev 54.23%; Δ 0.39% > 0%)
Interest Coverage Ratio: -1.55 > 6 (EBITDA TTM 131.1m / Interest Expense TTM 182.9m)
Altman Z'' 1.88
A: 0.09 (Total Current Assets 2.40b - Total Current Liabilities 1.37b) / Total Assets 11.66b
B: 0.15 (Retained Earnings 1.72b / Total Assets 11.66b)
C: -0.02 (EBIT TTM -284.4m / Avg Total Assets 11.99b)
D: 0.93 (Book Value of Equity 5.66b / Total Liabilities 6.07b)
Altman-Z'' Score: 1.88 = BBB
Beneish M -3.10
DSRI: 1.03 (Receivables 1.10b/1.10b, Revenue 6.55b/6.69b)
GMI: 1.04 (GM 32.13% / 33.56%)
AQI: 0.96 (AQ_t 0.73 / AQ_t-1 0.76)
SGI: 0.98 (Revenue 6.55b / 6.69b)
TATA: -0.10 (NI -551.4m - CFO 573.2m) / TA 11.66b)
Beneish M-Score: -3.10 (Cap -4..+1) = AA
What is the price of AVTR shares? As of May 20, 2026, the stock is trading at USD 7.64 with a total of 8,684,910 shares traded.
Over the past week, the price has changed by -6.49%, over one month by -10.12%, over three months by -17.05% and over the past year by -42.81%.
Is AVTR a buy, sell or hold? Avantor has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold AVTR.
  • StrongBuy: 6
  • Buy: 4
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AVTR price?
Analysts Target Price 9.9 29.1%
Avantor (AVTR) - Fundamental Data Overview as of 18 May 2026
P/E Forward = 8.2988
P/S = 0.794
P/B = 1.0152
Revenue TTM = 6.55b USD
EBIT TTM = -284.4m USD
EBITDA TTM = 131.1m USD
Long Term Debt = 3.78b USD (from longTermDebt, last quarter)
Short Term Debt = 37.0m USD (from shortTermDebt, last quarter)
Debt = 3.82b USD (corrected: LT Debt 3.78b + ST Debt 37.0m)
Net Debt = 3.54b USD (recalculated: Debt 3.82b - CCE 279.3m)
Enterprise Value = 8.74b USD (5.20b + Debt 3.82b - CCE 279.3m)
Interest Coverage Ratio = -1.55 (Ebit TTM -284.4m / Interest Expense TTM 182.9m)
EV/FCF = 19.91x (Enterprise Value 8.74b / FCF TTM 438.9m)
FCF Yield = 5.02% (FCF TTM 438.9m / Enterprise Value 8.74b)
FCF Margin = 6.70% (FCF TTM 438.9m / Revenue TTM 6.55b)
Net Margin = -8.42% (Net Income TTM -551.4m / Revenue TTM 6.55b)
Gross Margin = 32.13% ((Revenue TTM 6.55b - Cost of Revenue TTM 4.45b) / Revenue TTM)
Gross Margin QoQ = 31.66% (prev 31.49%)
Tobins Q-Ratio = 0.75 (Enterprise Value 8.74b / Total Assets 11.66b)
Interest Expense / Debt = 1.45% (Interest Expense 55.3m / Debt 3.82b)
Taxrate = 21.98% (12.2m / 55.5m)
NOPAT = -221.9m (EBIT -284.4m * (1 - 21.98%)) [loss with tax shield]
Current Ratio = 1.76 (Total Current Assets 2.40b / Total Current Liabilities 1.37b)
Debt / Equity = 0.68 (Debt 3.82b / totalStockholderEquity, last quarter 5.59b)
Debt / EBITDA = 26.98 (Net Debt 3.54b / EBITDA 131.1m)
Debt / FCF = 8.06 (Net Debt 3.54b / FCF TTM 438.9m)
Total Stockholder Equity = 5.75b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.60% (Net Income -551.4m / Total Assets 11.66b)
RoE = -9.59% (Net Income TTM -551.4m / Total Stockholder Equity 5.75b)
RoCE = -2.98% (EBIT -284.4m / Capital Employed (Equity 5.75b + L.T.Debt 3.78b))
 RoIC = -2.28% (negative operating profit) (NOPAT -221.9m / Invested Capital 9.72b)
 WACC = 5.58% (E(5.20b)/V(9.02b) * Re(8.85%) + D(3.82b)/V(9.02b) * Rd(1.45%) * (1-Tc(0.22)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -22.47 | Cagr: 0.01%
[DCF] Terminal Value 85.26% ; FCFF base≈529.9m ; Y1≈478.7m ; Y5≈414.5m
[DCF] Fair Price = 13.09 (EV 12.47b - Net Debt 3.54b = Equity 8.94b / Shares 682.8m; r=6.0% [WACC]; 5y FCF grow -12.00% → 3.0% )
EPS Correlation: -87.67 | EPS CAGR: -18.73% | SUE: -3.23 | # QB: -1
Revenue Correlation: -90.34 | Revenue CAGR: -4.92% | SUE: 2.06 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.19 | Chg30d=-3.67% | Revisions=-50% | Analysts=16
EPS next Quarter (2026-09-30): EPS=0.21 | Chg30d=-0.92% | Revisions=-7% | Analysts=16
EPS current Year (2026-12-31): EPS=0.79 | Chg30d=-0.03% | Revisions=+0% | GrowthEPS=-12.3% | GrowthRev=-0.8%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-0.34% | Revisions=+29% | GrowthEPS=+8.0% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -50%